Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: The present invention concerns double-stranded NF-?B decoy oligodeoxynucleotide (NF-?B dsODN) molecules that contain a core sequence capable of specific binding to an NF-?B transcription factor. In a particular aspect, the invention concerns NF-?B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-?B decoy molecules with improved binding affinity to p65.

Abstract: The present invention concerns double-stranded NF-?B decoy oligodeoxynucleotide (NF-?B dsODN) molecules that contain a core sequence capable of specific binding to an NF-?B transcription factor. In a particular aspect, the invention concerns NF-?B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-?B decoy molecules with improved binding affinity to p65.

Abstract: The present invention concerns methods and formulations for non-parental delivery of nucleic acid molecules to cells. In particular, the present invention relates to methods and formulations that enhance the transport of poly- and oligonucleotides across biological membranes.

Abstract: The invention concerns double-stranded HIF decoy oligodeoxynucleotide (dsODN) molecules comprising a core sequence that is capable of specific binding to a HIF transcription factor, compositions containing such molecules, and their use in the treatment of various diseases and pathologic conditions associated with the regulation of gene transcription by a HIF transcription factor.

Abstract: The present invention concerns double-stranded NF-?B decoy oligodeoxynucleotide (NF-?B dsODN) molecules that contain a core sequence capable of specific binding to an NF-?B transcription factor. In a particular aspect, the invention concerns NF-?B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-?B decoy molecules with improved binding affinity to p65.

Abstract: The invention concerns E2F oligonucleotide decoy molecules with improved properties. In particular, the invention concerns a double-stranded E2F decoy oligodeoxynucleotide (dsODN) molecule comprising a core sequence that is capable of specific binding to an E2F transcription factor, flanked by 5? and 3? sequences, wherein (i) the core sequence consists of about 5 to 12 base pairs; (ii) the molecule comprises an about 12 to 28 base-pair long double-stranded region composed of two fully complementary strands; and (iii) the E2F dsODN binds to said E2F transcription factor with a binding affinity that is at least about 5-fold of the binding affinity of a reference decoy molecule shown in FIG. 1 (SEQ ID NOS: 1 and 2), as determined by a competitive gel mobility shift binding assay performed on nuclear extract from THP-1 cells.